Key statistics dashboard for Mirum Pharmaceuticals, Inc. (MIRM). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia.
Stock Data
| Price | $97.37 |
| Market Cap | $5.9B |
| Enterprise Value | $6.16B |
| Beta | 0.52 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -6.76 |
| Price / Book | -598.43 |
| P/S | 9.71 |
| EV/EBITDA | -7.92 |
| EV/Sales | 9.96 |
| EV/FCF | -13.44 |
| P/FCF | -13.10 |
| Earnings Yield | -14.46% |
| FCF Yield | -8.00% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 81.70% |
| EBIT Margin | -129.88% |
| EBITDA Margin | -125.68% |
| Operating Margin | -17.42% |
| Net Margin | -139.18% |
| Return on Equity | -410.20% |
| Return on Assets | -82.32% |
| Return on Invested Capital | -13.09% |
| Return on Capital Employed | -13.09% |
Financial Health
| Current Ratio | 2.86 |
| Quick Ratio | 2.74 |
| Cash Ratio | 1.48 |
| Debt / Equity | -72.97 |
| Debt / Assets | 72.78% |
| Net Debt / EBITDA | -0.55 |
| Interest Coverage | -8.01 |
| Piotroski F-Score | 6 |
| Altman Z-Score | 4.42 |
Per-Share Data
| Revenue per share | 9.75 |
| Book Value per share | -0.16 |
| Cash per share | 6.92 |
| FCF per share | -7.23 |
| Tangible Book Value per share | -4.07 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 1 |
| Buy | 17 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 18 |
| Avg rating (1-5) | 1.06 |
Related companies: ACAD · ADMA · BLTE · DYN · LGND · PRAX · RARE
Explore sector: Healthcare · Biotechnology
More sections of MIRM: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks